Management of Metastatic Castration-resistant Prostate Cancer
Management of Metastatic Castration-resistant Prostate Cancer Abstract The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. … Click here for more.
Management of Metastatic Castration-resistant Prostate Cancer Read More »